Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating expenses:
Research and development	$ 2,255,584	$ 2,989,558
General and administrative	2,504,001	1,215,885
Total operating expenses	4,759,585	4,205,443
Loss from operations	(4,759,585)	(4,205,443)
Grant income	35,657	8,670
Interest (expense) income, net	(271,775)	1,078
Other income, net		997
Total other (expense) income	(236,118)	10,745
Net loss and comprehensive loss	(4,995,703)	(4,194,698)
Reconciliation to net loss attributable to common stockholders:
Net loss and comprehensive loss	(4,995,703)	(4,194,698)
Accretion of preferred stock to redemption value	(943,297)	(1,015,371)
Net Loss attributable to common stockholders	$ (5,939,000)	$ (5,210,069)
Net loss per share attributable to common stockholders, basic and diluted	$ (1.06)	$ (7.07)
Weighted average number of common shares used in computing net loss per share attributable to common stockholders, basic and diluted	5,605,151	737,016